Safety and efficacy of entecavir for the treatment of chronic hepatitis B

Clicks: 243
ID: 6465
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #1,355 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Safety and efficacy of entecavir for the treatment of chronic hepatitis B Melissa OsbornDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USAAbstract: Entecavir is a cyclopentyl deoxyguanosine analog that was approved for the treatment of the hepatitis B virus (HBV) in 2005. In Phase III trials, it showed potent HBV suppression with drops of 6- to 7-log copies/mL in HBV DNA at 1 year. In addition, rates of genotypic resistance in nucleos(t)ide-naïve patients are low, reaching only 1.2% after 6 years. Safety and efficacy have been established in compensated cirrhosis and HIV-coinfected patients. Studies in decompensated cirrhosis also show efficacy. Because of potent viral suppression and a large genetic barrier to resistance, entecavir is now a first-line choice in most HBV treatment guidelines and has become an integral part of the HBV treatment armamentarium.Keywords: hepatitis B, therapy, entecavir
Reference Key
melissa2011safetyinfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Melissa Osborn and
Journal Infection and drug resistance
Year 2011
DOI
10.2147/IDR.S4188
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.